Abstracts tagged "C-reactive protein (CRP)"

Abstract Number: 649 • 2018 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on a Quick Quantitative CRP Assay Performs Similarly Well to ASDAS Based on Conventional CRP in Patients with Axial Spondyloarthritis
Fabian Proft¹, Burkhard Muche¹, Laura Spiller¹, Valeria Rios Rodriguez¹, Judith Rademacher¹, Anne-Katrin Weber¹, Susanne Lueders², Mikhail Protopopov¹, Inge Spiller¹, Joachim Sieper³ and Denis Poddubnyy^3,4, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ³Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁴German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite index to assess disease activity in patients with axial spondyloarthritis (axSpA). According to the…
Abstract Number: 1326 • 2018 ACR/ARHP Annual Meeting
Does Testing for SAA Is More Beneficial Than CRP for the Follow-up of Patients with Familial Mediterranean Fever ?
Serdal Ugurlu¹, Oguzhan Selvi², Bilgesu Ergezen¹ and Huri Ozdogan¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: In order to follow subclinical inflammation and adjust the therapy for an optimal disease control, clinicians seek for readily accessible, affordable and reproducible markers.…
Abstract Number: 537 • 2017 ACR/ARHP Annual Meeting
No Effect of Baseline Serum CRP Levels on Clinical Efficacy Parameters in Rheumatoid Arthritis Patients Treated with Filgotinib: Post Hoc Analysis from Two Phase 2B Studies
Arthur Kavanaugh¹, Annegret Van der Aa², Corinne Jamoul², Chantal Tasset², Pille Harrison² and René Westhovens³, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Galapagos NV, Mechelen, Belgium, ³Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium
Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…
Abstract Number: 1352 • 2017 ACR/ARHP Annual Meeting
The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis
Craig Scoville¹, Jessica L. Suboticki², Sheng Zhong³ and Edward C. Keystone⁴, ¹Idaho Falls Arthritis Clinic, Idaho Falls, ID, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Elevated C-reactive protein (CRP) is often used as an entry criterion in clinical trials (CT) with rheumatoid arthritis (RA) patients (pts), resulting in the…
Abstract Number: 1437 • 2017 ACR/ARHP Annual Meeting
C-Reactive Protein Levels in Patients with or without Structural Progression: A Post-Hoc Analysis from a Phase 3 Tofacitinib Trial
Roy Fleischmann¹, Carol A Connell², Haiyun Fan³ and Sander Strengholt⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Capelle aan den IJssel, Netherlands
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We examined high sensitivity C-reactive protein (hsCRP) levels in relation…
Abstract Number: 1523 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies
Jürgen Braun¹, Joachim Sieper², Robert B.M. Landewé³, Xenofon Baraliakos¹, Corinne Miceli-Richard⁴, Ruvie Martin⁵, Brian Porter⁵, Kunal Gandhi⁵ and Désirée van der Heijde⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁴Department of Rheumatology, Hôpital Bicêtre, Paris, France, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Inhibition of IL-17A with secukinumab is an approved therapy for patients (pts) with AS.1 It has been previously reported that response rates with TNFα…
Abstract Number: 1954 • 2017 ACR/ARHP Annual Meeting
Association of CRP with BMI in Males and Females
Taik Kim¹, Stephen J. Ganocy², Maria Antonelli³, Douglas Einstadter⁴ and Stanley Ballou¹, ¹Rheumatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Department of Medicine/Division of Rheumatology, Case Western Reserve University School of Medicine, MetroHealth Medical Center, Cleveland, OH, ⁴Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: C-reactive Protein (CRP) is an inflammatory marker commonly used to help aid in diagnosis, assess disease activity or monitor response to therapy. It is…
Abstract Number: 2117 • 2017 ACR/ARHP Annual Meeting
C-Reactive Protein and Serum Amyloid a in Sepsis, Acute Appendicitis and Familial Mediterranean Fever
Oguzhan Selvi¹, Serdal Ugurlu², Murat Bolayirli³, Kenan Barut⁴, Sezgin Sahin⁴, Amra Adrovic⁴, Mustafa Akker⁵, Bilgesu Ergezen⁶, Osman Simsek⁷, Ozgur Kasapcopur^4,8 and Huri Ozdogan¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Biochemistry, Istanbul, Turkey, ⁴Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ⁵Department of Anesthesiolog, Sisli Hamidiye Training and Research Hospital, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁷Istanbul University, Cerrahpasa Medical Faculty, Department of General Surgery, Istanbul, Turkey, ⁸Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy
Background/Purpose: Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent inflammatory attacks. Attacks are accompanied by substantial increase in acute phase reactants such…
Abstract Number: 2212 • 2017 ACR/ARHP Annual Meeting
A Metabolite of C-Reactive Protein, a Marker of Disease Actvity, Is Prognostic of Radiographic Knee OA
Anne C. Bay-Jensen¹, Asger R. Bihlet², Inger Byrjalsen³, Jeppe Andersen⁴, Yi He⁵, Anne Sofie Siebuhr¹, Christian S. Thudium⁶, Bente J. Riis², Claus Christiansen² and Morten Asser Karsdal¹, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Clinical Development, Nordic Bioscience, Herlev, Denmark, ⁵Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ⁶Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: There are two major needs in clinical DMOAD development: Identifying a population with an active and progressive disease to demonstrate significant improvements by an…
Abstract Number: 2423 • 2017 ACR/ARHP Annual Meeting
Patients with Active Rheumatoid Arthritis but Normal Levels of Acute Phase Proteins Have Altered Regulatory T Cell Function and Rapidly Progress to Biological Therapies
Claire Bradford¹, Shashank Ramakrishnan¹, Andrew Cole², Coziana Ciurtin³, Elizabeth Jury¹ and Jessica Manson⁴, ¹Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ²Centre for Rheumatolofy Research, University College London, London, United Kingdom, ³Rheumatology Department, University College London, London, United Kingdom, ⁴University College London Hospitals NHS Trust, London, United Kingdom
Background/Purpose: An atypical subgroup of patients with seropositive rheumatoid arthritis (RA) was identified with active disease (confirmed by Power Doppler ultrasound (PDUS)) but normal levels…
Abstract Number: 2506 • 2017 ACR/ARHP Annual Meeting
In Ankylosing Spondylitis/Axial Spondyloarthritis Smoking Is Associated with a Dose Related Elevation in CRP, Worse Disease Activity and Worse Quality of Life over One Year
Simon Stebbings¹, Mary Wallace², Andrew A. Harrison³, Nicola Dalbeth⁴, Douglas White⁵, Lisa K. Stamp⁶, Daniel Ching⁷ and John Highton⁸, ¹Dunedin Hospital, Department of Rheumatology, Dunedin, New Zealand, ²Surgical Sciences, University of Otago, Dunedin, New Zealand, ³Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵Department of Rheumatology, Waikato Clinical School, Hamilton, New Zealand, ⁶University of Otago, Christchurch, New Zealand, ⁷Timaru Medical Specialists Ltd, Timaru, New Zealand, ⁸Dept of Medicine, Univ of Otago Med Sch, Dunedin, New Zealand
Background/Purpose: Analysis of data from several cohort studies of patients with ankylosing spondylitis (AS) /axial spondyloarthritis (AxSpA) have confirmed earlier suggestions that current smokers have…
Abstract Number: 116 • 2017 Pediatric Rheumatology Symposium
Arthritis as First Presenting Symptom of Inflammatory Bowel Disease: A Case Control Study
Kathryn Phillippi¹, Thomas Sferra², Nora Singer³ and Elizabeth Brooks⁴, ¹Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, ²Pediatric Gastroenterology, Rainbow Babies and Children's Hospital/Case Medical Center, Cleveland, OH, ³MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio, Cleveland, OH, ⁴Division of Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, Cleveland, OH
Background/Purpose: Inflammatory bowel disease (IBD) is associated with extra-intestinal manifestations, the most common of which is arthralgia/arthritis. 4.1- 15% of patients with inflammatory bowel disease…
Abstract Number: 1560 • 2016 ACR/ARHP Annual Meeting
A Unique Immune Signature in Patients with Active Rheumatoid Arthritis but Normal C-Reactive Protein Levels: Potential for New Therapeutic Targets?
Claire Bradford¹, Rosa González-Serrano¹, Andrew Cole¹, Shashank Ramakrishnan¹, Giampiero Marra¹, Coziana Ciurtin², Elizabeth Jury¹ and Jessica Manson³, ¹Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ²Rheumatology Department, University College London, London, United Kingdom, ³Rheumatology Department, University College London Hospital, London, United Kingdom
Background/Purpose: Using musculoskeletal ultrasound (US) to assess joint erosions and disease activity in patients with seropositive rheumatoid arthritis (RA) an atypical subgroup was identified with…
Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting
The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Alan Glicklich¹, Paul Grayson¹, Christophe Blanchetot², Qing Zhou³ and Anke Kretz-Rommel¹, ¹Bird Rock Bio, Inc, La Jolla, CA, ²Argenx, Ghent, Belgium, ³Genor BioPharma, Shanghai, China
Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…
Abstract Number: 2161 • 2016 ACR/ARHP Annual Meeting
Association Between Inflammation and Systolic Blood Pressure at Normal and High C-Reactive Protein Levels
Zhi Yu¹, Kathleen Vanni², Seoyoung C. Kim³, Daniel H. Solomon⁴, Shawn N. Murphy⁵ and Katherine Liao⁶, ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Research Computing, Partners Healthcare Systems, Boston, MA, ⁶Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: While inflammation is linked with higher blood pressure (BP) in the general population, few studies have examined this relationship in patients with elevated levels…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].